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Abstract
Purposes The purposes of this study were to investigate the
incidence of lymphedema in patients with breast cancer during
and after adjuvant treatment with docetaxel, doxorubicin, and
cyclophosphamide (TAC), to identify predictors for develop-
ment of lymphedema, and to describe consequences in daily
life in relation to lymphedema.
Methods This is a prospective study with measurements be-
fore chemotherapy (T0), during chemotherapy before cycle 2
(T1), cycle 4 (T2), and 1 month after completion of treatment
(T3). Volume change was monitored using tape measure-
ments. Lymphedema was defined as ≥ 10% volume differ-
ence. Linear mixed-effect models were estimated to analyze
differences in arm volume and consequences in daily life (total
score and domain scores of the Lymph-International
Classification of Functioning (ICF) questionnaire) over time
and to identify treatment and patient characteristics as predic-
tors for changes in volume.
Results Forty-eight patients completed all measurements.
Volume did not change during TAC treatment. One month
after treatment, volume was significantly increased compared
to T0-T2, and 12 patients (25%) had developed lymphedema.
Axillary lymph node dissection was associated with lymph-
edema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with
and without lymphedema, 1 month after completion (T3), the
Lymph-ICF questionnaire showed significant limitations in
physical function compared to T0-T2. In patients with lymph-
edema at T3, a significant association between volume and
total score on the Lymph-ICF questionnaire on physical func-
tion and mobility activities was observed.
Conclusions One month after treatment in 12 patients (25%),
volume difference increased over 10%. Axillary lymph node
dissection was predictive for development of lymphedema.
All patients, but more patients with lymphedema, perceived
difficulties in activities in daily life after treatment.
Keywords Breast neoplasms . Lymphedema . Adjuvant
chemotherapy . Activities of daily living . Quality of life
Introduction
Lymphedema is a common side effect of breast cancer treat-
ment, usually starting within 2 years after treatment [1].
Patients with lymphedema suffer not only from swelling but
also from other impairments in functions and limitations in
activities in daily life, as described in the core set lymphedema
based on the International Classification of Functioning (ICF)
[2]. Lymphedema is defined as a volume difference between
upper extremities of ≥ 10% [3], resulting in limitations in arm
use during daily activities, emotional distress, restrictions in
social activities, and limited work abilities [2, 4, 5].
The estimated incidence of lymphedema 5 years after
breast cancer treatment is 16.6%, and increase in arm volume
is related to axillary lymph node dissection, the number of
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lymph nodes dissected, mastectomy, radiotherapy to the axil-
la, and a bodymass index over 25 kg/m2 [1, 6]. Recent studies
have indicated that the use of adjuvant cytotoxic treatment
may be associated with development of lymphedema after
completion of treatment, especially regimens containing
anthracyclines and taxanes [6–14]. Swelling may decline over
time, as a result of lymphedema treatment or due to spontane-
ous recovery of transient swelling within 3 months [13, 14].
Adjuvant chemotherapy has been shown to improve survival
in patients with early-stage breast cancer. Second and third
generation schemes are more effective in survival compared
to first generation schemes [15]. A frequently used third gen-
eration regimen consists of docetaxel, doxorubicin, and cyclo-
phosphamide (TAC) [16].
Although the prevalence of lymphedema in the arm after
completion of TAC has been reported [11–14], development
of lymphedema during treatment with TAC and limitations in
daily activities in relation to lymphedema during and after
TAC are unknown. Early detection of lymphedema and con-
sequently early intervention can lessen treatment burden and
increase the cost-effectiveness of care [17]. Therefore, it is
clinically relevant to obtain insight in changes in volume dif-
ferences or the amount of extracellular fluid in an early stage.
The purpose of this study is to answer the following ques-
tions: (1) what is the change in arm volume during adjuvant
treatment with TAC, and do patients develop lymphedema as
defined by a volume difference between upper extremities of
≥ 10%, (2) which predictors for development of lymphedema
can be identified, and (3) which consequences in daily life are
related to the presence of lymphedema?
Methods
Study design
We conducted a prospective cohort study inwhich patients with
unilateral breast cancer were scheduled for adjuvant cytotoxic
treatment with six cycles of TAC. Patients were measured at
four time points: at baseline before cycle 1 (T0), during chemo-
therapy before cycle 2 (T1) and cycle 4 (T2), and 1 month after
the 6th cycle (T3). Three months after completion, the Lymph-
ICF questionnaire was sent to the patients (T4).
Patient population
Patients, both female and male, with tumor stages I–III, sched-
uled for adjuvant cytotoxic treatment with TAC at the
Radboud University Medical Center were invited by a spe-
cialized nurse (WB) to participate in this study. Patients were
included between August 2011 and January 2015. Surgery
was completed, as well as radiotherapy if indicated, before
the start of TAC. Exclusion criteria were recurrence or second
cancer and insufficient understanding of Dutch language for
filling out the questionnaire. Formal ethical approval was
waived by the Medical Ethical Committee of the Radboud
University Medical Center. The study was registered under
number 2011/234. All participants signed informed consent
before the first measurement. We calculated the sample size
based on arm volume difference as primary endpoint. A priori,
a dropout of 10%was taken into account. To detect changes at
a two-sided significance level of 5% and an estimated power
of 80%, we planned to enroll 50 patients.
Chemotherapy
Docetaxel (75 mg/m2), doxorubicin (50 mg/m2), and cyclo-
phosphamide (500 mg/m2) were administered intravenously
on day 1 of a three-weekly cycle for a total of six courses.
Dexamethasone was administered 8 mg orally twice daily for
3 days, starting the day before start of TAC during all cycles.
Measurements
Demographic and tumor characteristics, type of surgery,
axillary lymph node dissection, tumor stage, nodal
stage, tumor grade, adjuvant radiotherapy, radiotherapy
to the axilla or supraclavicular region, weight, and
height were derived from electronic health records of
the included patients. Early termination of TAC or dose
reduction was registered, as well as the reason for the
early stop and change of cytotoxic agents. Weight was
registered before the first and after the last cycle to
determine body mass index (BMI) and weight changes.
Volume of both arms was measured by tape measure-
ment [18], and impairments in functions and limitations
in activities in daily life were measured by the Lymph-
ICF questionnaire [19]. Measurements were performed
by three physiotherapists (CB, RD, JH), experienced in
measuring arm volume. Investigators were blinded for
results of prior measurements. The measurement proto-
col was described in detail to reduce measurement error
and, if possible, patients were measured by the same
therapist throughout the whole study. All patients with
a volume difference ≥ 10%, at any time point, were
referred for treatment. Both upper limbs were measured
by tape measurement with 10 cm intervals up to 40 cm,
starting at the ulnar styloid process. Position of the arm
during measurement was in 90° flexion of the shoulder
with the elbow extended. Hands were supported on a
pillow. To calculate volume, the conical formula was
used [18]. Volumes between both upper extremities
were converted to percentage differences (relative vol-
ume, in short mentioned as volume in this article). Tape
measurement is a reliable measurement instrument, with
excellent intra- and intertest-retest reliability (ICC 0.99
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and 0.98, respectively) and good validity (0.80–1.00)
compared to water volumetry when a standardized protocol
is used [18].
Volume differences, based on the tape measurement, were
computed at all four time points. A volume difference ≥ 10%
between both upper extremities was indicated as swelling or
development of lymphedema [3]. To get insight in outcomes
between patients without and with lymphedema 1 month after
completion, and to get insight in the association between vol-
ume differences and impairments in functions and limitations
in activities in daily life, the patient group was dichotomized
in two categories: with lymphedema and without lymphedema
1 month after completion of TAC (T3).
The Lymph-ICF questionnaire for the upper extremity was
used to get insight in impairments in functions and limitations
in activities in daily life [19]. The Lymph-ICF is a quality of
life questionnaire developed for patients with lymphedema,
with 29 items over five domains: physical function, mental
function, household activities, mobility activities, and social
activities. Each item can be scored between 0 and 100 on a
horizontal line of 100 mm. Domain scores and the total score
can be calculated from the items, both resulting in a score
between 0 and 100. A higher score means more impairment
in functions or limitation in activities: scores under 25 indicate
a minor problem, scores between 25 and 50 a moderate
problem, and scores more than 50 a severe problem.
Measurement properties of the Lymph-ICF have been
studied before and showed a fair to excellent reliability
for all scales (r = 0.65–0.93) compared to volume mea-
surements [19]. Patients filled in the Lymph-ICF ques-
tionnaire at every measurement point. To get insight in
recovery after TAC, 3 months after the last TAC (T4),
the Lymph-ICF questionnaire was sent to the patient for
a final measurement.
Statistical analysis
Descriptive analyses were used to describe patient character-
istics, treatment characteristics, the number of patients with
lymphedema, and the scores of the Lymph-ICF questionnaire
in total and its domains.
To analyze differences in volume and consequences
in daily life over time (total score and domain scores on
the Lymph-ICF questionnaire) and to identify treatment
and patient characteristics as predictors for changes in
volume, linear mixed-effect models were used. We esti-
mated a random intercept model with volume difference
as dependent variable, and we estimated separate
models with total score and domain scores of the
Lymph-ICF questionnaire as dependent variables. To in-
dicate predictors for lymphedema, univariate analysis
was used to analyze the association between volume
difference and type of surgery, surgery on dominant
side, axillary lymph node dissection, tumor stage, nodal
stage (N0 versus N1, N2, and N3), tumor grade (T1
versus T2 or 3), adjuvant radiotherapy, radiotherapy to
the axilla or supraclavicular region, and change of BMI
between T0 and T3. Variables with an association p < 0.20 in
the univariate analysis were included into the model as
independent variables.
To analyze the association between volume differ-
ences and impairments in functions and limitations in
activities after completion of TAC, Pearson’s correlation
coefficients between volume and the outcomes of the
Lymph-ICF questionnaire (total score and domain scores)
were calculated for the total population. To analyze the
relation between scores of the Lymph-ICF questionnaire
and lymphedema, patients were dichotomized in patients
without lymphedema and patients with lymphedema at
1 month after completion of TAC (T3). In both groups,
the association between the volume and the scores of
the Lymph-ICF questionnaire, its five domains, and individual
items of the physical function domain and mobility activities
domain (T3 and T4) were analyzed, using Spearman’s
correlations.
Correlations between measurement outcomes were
interpreted as follows: r between 0.40 and 0.75 is fair to good;
r > 0.75 is excellent [20].
For statistical analysis, SPSS version 22 was used.
Results
A total of 74 patients scheduled for adjuvant TAC were
invited to participate in the study. Fifty-one patients
consented to participate, one of these was male. Mean age
of the included patients was 51.3 years (30–68; SD 8.5).
Patient and tumor characteristics of these patients are sum-
marized in Table 1. Two patients switched treatment to FEC
(5-fluorouracil, epirubicin, and cyclophosphamide) after the
third and fourth cycles. One patient was treated without
docetaxel in the fourth cycle of TAC and stopped after this
cycle. Finally, 48 patients completed six cycles of TAC and
all follow-up measurements. Four of these 48 patients were
treated with reduced dose (75%) after the third (n = 2 pa-
tients), fourth (n = 1 patient), or fifth cycle (n = 1 patient)
(see Fig. 1).
Changes in arm volume and lymphedema measured
by tape measurement
Mean volume did not change during treatment but in-
creased significantly from 2.3% at T0 to 5.1% at 1 month
after completion of TAC (T3) (p = 0.01) (see Table 2). In
total, 15 patients showed increased volume of ≥ 10% dif-
ference in at least one measurement point. In three of the
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six patients, swelling was deemed transient: volume de-
creased under the cutoff point of 10% volume difference
within the study period, one of them without treatment.
Fulfilling our definition, lymphedema was observed first
in six patients during TAC treatment. These patients were
referred for lymphedema treatment: two patients were in-
dicated at baseline (T0), two before the second (T1), and
two before the fourth cycle during chemotherapy (T2).
One month after treatment (T3), lymphedema was ob-
served in 12 out of 48 patients (25%).
Predictors for of lymphedema
Axillary lymph node dissection, nodal stage, axillary
radiation, and difference in BMI identified between
1 month after completion of TAC (T3) and baseline
(T0) were variables with a correlation (p < 0.10) with
volume at T3 in the univariate analysis. The linear
mixed-effect model showed that axillary lymph node
dissection was the only factor significantly associated
with increased volume (ES 2.9%; 95% CI 0.02–5.7;
Table 1 Baseline patient, tumor,
and treatment characteristics Number of patients Frequency (%)
Sexes Female/male 50/1 98/2
Age (Mean-SD) 51.3 8.5
BMI (Mean-SD) 26.26 4.44
Surgery Dominant arm 25 (3 left, 22 right) 49
Non-dominant arm 26 (3 left, 23 right) 51
Mastectomy/lumpectomy 27/24 52.9/47.1
ALND/SNB 16/44 31.4/86.3
Tumor size ≤ 2 cm 22 43.1
2–5 cm 26 50.9
> 5 cm 3 5.9
Histology Ductal carcinoma 46 90.2
Lobular carcinoma 4 7.8
Other 1 2
Tumor stage Tis 1 2.0
T1 3 5.9
T1b 2 3.9
T1c 18 35.3
T1(m) 2 3.9
T2 17 33.3
T2(m) 7 13.7
T3 1 2.0
Nodal stage No 10 19.6
N0(i+)-isolated tumor cells 11 21.6
N1 10 19.6
N1(mi) micrometastasis 11 21.6
N(1a) 7 13.7
N(2a) 2 3.9
Tumor grade T0 1 2.0
T1 4 7.8
T2 27 49.0
T3 19 39.2
Estrogen receptor Positive/negative 45/6 85.2/14.8
Progesterone receptor Positive/negative 34/17 66.7/33.3
Radiotherapy 33 64.7
Boost tumor bed 18 35.3
Axillary/supraclavicular radiation 11 21.6
ALND axillary lymph node dissection, BMI body mass index, SNB sentinel node biopsy, cm centimeter,
SD standard deviation
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variance 9.5%, p < 0.05 (see Table 7); odds ratio 12.4;
95% CI 2.6–58.3; p < 0.01).
Impairments in functions and limitations in activities
in daily life
Mean total score of the Lymph-ICF questionnaire showed an
increase from 14.6 at baseline (T0) to 19.5 at 1 month after
completion of TAC (T3) and subsequently decreased to
16.5 at 3 months after completion of TAC (T4).
Longitudinal analysis showed no significant changes over
time except in the domain physical functioning. One month
after TAC completion, physical functioning showed a signif-
icant increase (p = 0.01) compared to T0–T2. Three months
after, TAC physical functioning improved, but scores
remained higher compared to T0 (p < 0.05) (Table 3).
The number of patients with moderate to severe problems
(scores ≥ 25) on the Lymph-ICF questionnaire decreased be-
tween T3 and T4. Looking at the number of patients without
lymphedema and with lymphedema, relatively more patients
with lymphedema experienced problems, especially in total
score, physical functioning, mobility activities, and social ac-
tivities, 1 and 3 months after treatment (T3, T4). Patients
without lymphedema reported more problems with mental
functions 1 month after treatment (see Table 4). One month
after completion of TAC, in patients with lymphedema, a sig-
nificant association was found between volume and the
Lymph-ICF total score (r = 0.66), the physical function do-
main (r = 0.77), the item scores for heaviness (r = 0.83) and
swelling (r = 0.71), and the mobility activities domain
(r = 0.66), as well the items activities above the head
(r = 0.71) and cycling (r = 0.72). Three months after comple-
tion of TAC, in patients with lymphedema, the significant
correlation between relative volume at T3 and the total
Lymph-ICF score (r = 0.70) and mobility activities
(r = 0.62) remained (see Table 5).
Discussion
During cytotoxic treatment with TAC, we observed no signif-
icant changes in volume between upper extremities in the total
study population. However, 1 month after completion of TAC,
volume was increased significantly, and 25% of the patients
had developed a volume difference over 10%, defined as
lymphedema. Also, in this population, axillary lymph node
dissection was predictive for development of lymphedema,
as was reported in earlier studies as well [6, 21]. The
Lymph-ICF questionnaire showed significant impairments in
the physical function domain at 1 and 3 months after comple-
tion. One month after treatment, 17 patients showed at least
moderate problems on the total score of the questionnaire and
reported problems in physical function, household activities,
mobility activities, and social activities. We observed a small
decline in the number of patients with health problems be-
tween 1 and 3 months after completion of TAC.
Reported prevalence of lymphedema, measured at a com-
parable time point after surgery in recent studies on breast
cancer, was comparable with our study at baseline [13, 14,
22, 23]. DiSipio et al. described in their systematic review a
prevalence of lymphedema of 10.3% (95%CI 6.2–16.7) at the
same time point as T3 in our study, after completion of cyto-
toxic treatment [1]. In relation to their study, the prevalence of
lymphedema at the endpoint in our study is higher. This could
be the effect of the adjuvant treatment with TAC as suggested
in a recent study indicating docetaxel as important risk factor
for onset of lymphedema, with a chance of developing lymph-
edema being 4.8 times higher when compared to other treat-
ment regimens [10] and reported in earlier studies as well
[7–9, 11–14]. Compared to our study, earlier studies on TAC
as a risk factor for lymphedema reported a higher prevalence
of lymphedema over two or more years after treatment with
TAC with 33.5% [12], 42.2% [14], and 32% after treatment,
declining to 23% at 6 months [13]. Although bio-impedance
spectroscopy (BIS) measures extracellular fluid more ade-
quately and good correlations between volume measurements
and BIS were found in case of swelling [18, 24–26], we
Table 2 Lymphedema measurements with tape at 10 cm distance,
calculated as relative volume difference between affected and
unaffected upper extremity
Mean (%) Standard error 95% Confidence Interval Significance
T0 2.282 .925 0.458–4.107
T1 2.180 .925 0.356–4.005 0.938
T2 2.689 .944 0.827–4.550 0.759
T3 5.708 .924 3.872–7.633 0.010*
T0 before TAC 1, T1 before TAC 2, T2 before TAC 4, T3 1 month after
TAC 6
*Significance at p < 0.05
Paents included in study
n=51
Paents denied to parcipate n=23
Reason:
Lymphedema n=2
Too much eﬀort n=8
Rather not n=7
Language problem n=1
Comorbidity n=1
Other reasons n=4
Paents treated following protocol
n=44
Eligible paents
n=74
Paents with interrupted treatment n=7
Early stop n=3
Dose reducon n=4
Fig. 1 Flowchart patient inclusion for measuring before, during, and
after adjuvant TAC
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decided not to add BIS in our measurement protocol to de-
crease patient load during the study. As results from different
studies can be compared, we decided to decrease patient load
during the study. The somewhat lower prevalence of lymph-
edema (25%) in our study may be the result of lymphedema
treatment of patients with a volume difference over 10%, later
onset of lymphedema, as well as recent developments in sup-
portive care encouraging patients to stay active during treat-
ment with at least 30 min of moderate daily physical activity
[27]. Referral to physical therapy or lymphedema treatment
was reported in one other study [10]. Our analysis of
predictive factors for development of lymphedema early after
treatment with TAC confirms the findings of Lee et al.: axil-
lary lymph node dissection is an important risk factor for
development of lymphedema [13].
Concerning the Lymph-ICF questionnaire, problems were
apparent over a longer period, in patients with and without
lymphedema. Looking to the results in Table 4, it can be
observed that the number of patients with problems on the
Lymph-ICF questionnaire differs between groups, while
Tables 5 and 6 point out that volume increase is associated
with more problems at the Lymph-ICF questionnaire. This
Table 3 Lymph-ICF
questionnaire and its domains at
baseline before chemotherapy
(T0), during chemotherapy before
TAC 2 (T1) and before TAC 4
(T2), 1 month after completion of
TAC 6 (T3), and 3 months after
completion of TAC 6 (T4)
Measurement point Number Mean Standard Error Significance 95% confidence interval
Total score
T0 51 14.63 2.20 10.29–18.97
T1 51 11.31 2.20 0.29 6.97–15.66
T2 49 12.98 2.25 0.60 8.55–17.41
T3 48 19.46 2.27 0.13 14.98–23.93
T4 48 16.52 2.27 0.55 12.05–21.00
Physical function
T0 51 9.80 2.19 5.49–14.12
T1 51 6.90 2.19 0.35 2.58–11.22
T2 49 9.96 2.24 0.96 5.55–14.37
T3 48 17.79 2.26 0.01* 13.34–22.24
T4 48 16.67 2.26 0.03* 12.22–21.12
Mental function
T0 51 11.75 2.23 7.36–16.13
T1 50 7.74 2.25 0.21 3.31–12.17
T2 49 8.18 2.27 0.26 3.71–12.66
T3 48 11.90 2.94 0.96 7.38–16.42
T4 48 9.46 2.94 0.48 4.94–13.98
Household activities
T0 51 14.98 2.87 9.79–20.63
T1 51 13.71 2.87 0.75 8.06–19.35
T2 49 12.02 2.93 0.47 6.26–17.78
T3 48 21.38 2.96 0.12 15.55–27.20
T4 48 16.81 2.96 0.66 10.99–22.63
Mobility activities
T0 51 18.14 2.74 12.73–23.54
T1 51 13.73 2.74 8.32–19.13
T2 49 14.00 2.80 0.26 8.49–19.52
T3 48 20.58 2.83 0.29 15.01–26.12
T4 48 19.31 2.83 0.54 13.74–24.89
Social activities
T0 51 19.20 3.19 12.92–25.47
T1 51 16.45 3.19 0.54 10.18–22.73
T2 49 19.35 3.25 0.97 12.94–25.75
T3 48 23.79 3.28 0.32 17.32–30.26
T4 48 18.21 3.28 0.83 11.74–25.68
*Significance at p < 0.05
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Table 5 Correlations between
volume measured with tape
measurement and Lymph-ICF
questionnaire 1 month after com-
pletion of TAC (T3) in patients
without and with lymphedema
Relative
volume
Total
score
Physical
function
Mental
function
Household
activities
Mobility
activities
Social
activities
Patients without lymphedema (n = 36)
Relative
volume
1.000
Total score − 0.341* 1.000
Physical
function
− 0.014 0.696** 1.000
Mental
function
− 0.368* 0.660** 0.324 1.000
Household
activities
− 0.479** 0.885** 0.526** 0.617** 1.000
Mobility
activities
− 0.380* 0.853** 0.665** 0.496** 0.833** 1.000
Social
activities
− 0.305 0.828** 0.326 0.657** 0.752** 0.689** 1.000
Patients with lymphedema (n = 12)
Relative
volume
1.000
Total score 0.658* 1.000
Physical
function
0.768** 0.676* 1.000
Mental
function
0.445 0.667* 0.320 1.000
Household
activities
0.449 0.844** 0.488 0.557 1.000
Mobility
activities
0.660* 0.865** 0.602* 0.585* 0.849** 1.000
Social
activities
0.180 0.739** 0.145 0.367 0.684* 0.607* 1.000
r between 0.40 and 0.75 is fair to good; r > 0.75 is excellent
*Significance < 0.05 (two-tailed); **significance < 0.01 (two-tailed)
Table 4 Patients with moderate (≥ 25; < 50) and severe (≥ 50) problems indicated by the Lymph-ICF questionnaire after treatment with TAC
One month after completion (T3) Three months after completion (T4)
Reported score ≥ 25; < 50 ≥ 50 total ≥ 25; < 50 ≥ 50 total
Total score 12 5 17 6 4 10
Without lymphedema 9 3 12 4 3 7
With lymphedema 3 2 5 2 1 3
Physical function 10 4 14 6 4 10
Without lymphedema 5 3 8 4 3 7
With lymphedema 5 1 6 2 1 3
Mental function 3 3 6 – 4 4
Without lymphedema 2 3 5 – 3 3
With lymphedema 1 – 1 – 1 1
Household activities 11 6 17 6 5 11
Without lymphedema 9 4 13 5 3 8
With lymphedema 2 2 4 1 2 3
Mobility activities 9 7 16 11 6 17
Without lymphedema 6 5 11 9 4 13
With lymphedema 3 2 5 2 2 4
Social activities 10 8 18 7 8 15
Without lymphedema 7 5 12 7 5 12
With lymphedema 3 3 6 – 3 3
Patients without lymphedema n = 36; patients with lymphedema n = 12
Scores in italic: total number of patients with problems on the mentioned item
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means that all patients, with or without lymphedema, experi-
enced problems and the Lymph-ICF questionnaire revealed
health problems in the whole study-population. However,
lymphedema increased the scores. Compared to the literature,
in a study with FEC (fluorouracil, epirubicin, and cyclophos-
phamide), one third of the patients still had problems as well
[28] and problems related to work were reported in a recent
systematic review [4]. Especially mobility activities are an
indication for decreased social contacts and participation in
community life and work, which are important factors for
quality of life [29, 30]. Moderate- to high-intensity exercises
during chemotherapy could have limited the decrease in ac-
tivities during adjuvant treatment, as was reported in an earlier
study in a comparable population, reporting significant posi-
tive effects of exercise on physical function, fatigue, and che-
motherapy completion rates [31].
The item scores of heaviness and swelling were significant-
ly associated with volume in patients with lymphedema.
These self-reported outcomes can indicate lymphedema of
the affected upper extremity [26, 32, 33], can be used as a
patient’s reported outcome for lymphedema, and are support-
ive in the clinical decision making on volume measurement
and referral for lymphedema treatment. When moderate to
severe problems are reported on the Lymph-ICF question-
naire, referral to specialized health care should be considered
to improve functions and activities as soon as possible [34,
35]. In agreement with a previous systematic review of the
literature [6], many factors play a role in complaints of patients
after medical treatment for breast cancer. For the patient as
well as the healthcare provider, it is important to know the
origin of the complaints. It is unclear why the item cycling
within the domain mobility activities has high scores in most
of the patients; probably, this can be related to reduced cardio-
vascular function as an adverse effect of TAC [16] and to
fibroses of the breast in patients treated with lumpectomy
and radiotherapy (OR 7) [36] or pain after radiotherapy of
the chest wall, as was reported by Levangie et al. in 26% of
the patients, leading to reduced daily activities [5]. Limitations
in activities above the head can be related to declined shoulder
mobility, which is often described as adverse effect of axillary
node dissection and/or axillary radiotherapy, or declined mus-
cle strength or shoulder coordination, described as adverse
effects of axillary node dissection and chemotherapy [6, 37].
This is the first study describing arm volume during TAC
as an objective measurement of lymphedema in combination
with patient reported outcome measures on physical and men-
tal function, household activities, mobility activities, and so-
cial activities. However, some limitations should be
considered.
Preoperative measurements were not incorporated in our
measurement protocol, although such measurements have
been recommended in the literature [38–42]. However, the
first measurement was started within 3 months post-
operatively and lymphedema is rarely reported within the first
Table 6 Correlations between relative volume measured with tape measurement and items of the Lymph-ICF questionnaire 1 month after completion
of TAC (T3) in patients with lymphedema (n = 12)
Relative
volume
Heaviness Swelling Strength Tense
feeling
Activities
above head
Lifting
heavy
objects
Sleeping on
affected side
Working on
computer
Walking
> 2 km
Cycling
Relative
volume
1.000
Heaviness 0.830** 1.000
Stiffness 0.516 0.525
Swelling 0.709** 0.872** 1.000
Strength 0.550 0.797** 0.753** 1.000
Tense feeling 0.421 0.616* 0.796** 0.753** 1.000
Activities
above head
0.705* 0.774** 0.814** 0.778** 0.618* 1.000
Lifting heavy
objects
0.564 0.613* 0.434 0.648* 0.219 0.734** 1.000
Sleeping on
affected
side
0.348 0.287 0.113 0.644 − 0.157 0.673* 0.850** 1.000
Working on
computer
0.500 − 1.000** − 0.500 0.500 0.500 0.500 0.500 0.500 1.000
Waling
> 2 km
0.295 0.116 0.095 0.363 0.329 0.286 0.277 0.540 1.000** 1.000
Cycling 0.723* 0.492 0.322 0.610 0.340 0.729* 0.732* 0.962** 1.000** 0.948** 1.000
r between 0.40 and 0.75 is fair to good; r > 0.75 is excellent
*Significance < 0.05 (two-tailed); **significance < 0.01 (two-tailed)
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months post-operatively. Moreover, this time point was found
as significant predictor by Sun et al. for over- and
underdiagnoses [40]. Lymphedema defined as relative volume
change (RVC) compared to baseline as used by Sun et al. is a
different definition compared to our definition using relative
volume difference (RVD) between extremities. We used RVD
following the commonly used definition in the literature [1, 6].
Future studies need to point out which of the definitions is
most adequate. Furthermore, patient and treatment character-
istics should be analyzed in relation to volume change during
a longer follow-up with more measurement occasions. A rath-
er conservative cutoff point of 10% between both upper ex-
tremities was defined as lymphedema, based on the smallest
detectable change in tape measurement (6.6%, with excellent
interrater reliability (ICC inter 0.98) [18]. Probably, a cutoff
point of 5% would have increased the number of patients with
(subclinical) lymphedema and transient edema.
Although the sample was large enough to distinguish
changes in volume difference during the study period, a larger
sample size and a longer follow-up might have indicated more
risk factors for development of lymphedema over time, and a
higher prevalence of lymphedema, as reported in earlier stud-
ies on TAC and docetaxel [8–12, 14, 40]. As nomeasurements
were performed between cycles 4 and 6, the exact time point
of onset of lymphedema cannot be determined. A longer
follow-up would have enabled the distinction between
transient swelling from persistent lymphedema. Swelling can
be transient as a result of spontaneous recovery or by inter-
vention, as reported earlier [1, 8, 10, 13, 14]. In future research
and in clinical practice, volumemeasurements should be taken
at baseline and at least in the first follow-up visit after com-
pletion of TAC. Follow-up should be extended to differentiate
between transient swelling and lymphedema, reporting
lymphedema treatment as well.
Altogether, monitoring swelling seems to have added value
and seems to be clinically relevant.
Conclusion
In our population, arm volume increased significantly 1month
after treatment with TAC and in 12 out of 48 patients (25%)
relative volume difference increased over 10%. Axillary
lymph node dissection was predictive for development of
lymphedema. After treatment with TAC, all patients, but more
patients with lymphedema, perceived difficulties in activities
in daily life.
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Appendix
Table 7 Fixed effects of the
linear mixed-effect model in rela-
tion to predictive factors for in-
crease of relative volume at T3
Parameter Estimate Standard
error
p
value
95% confidence
interval
Intercept 1.68 0.63 0.01 0.44–2.93
ALND 2.86 1.17 0.05* 0.02–5.69
Nodal stage 1.44 1.09 0.20 − 0.72–3.60
Axillary radiation 0.65 2.75 0.81 − 4.78–6.08
BMI T3-T0 − 0.00 0.00 0.45 − 0.01–0.00
ALND * nodal stage − 0.26 3.16 0.94 − 8.82–8.30
ALND * axillary radiation 297.67 181.87 0.10 − 61.30–656.64
ALND * BMI T3-T0 2.02 0.74 0.07 − 0.26–4.30
Nodal stage * axillary radiation − 4.14 3.28 0.21 − 10.62–2.34
Nodal stage * BMI T3-T0 0.00 0.48 1.00 − 0.95–0.96
Axillary radiation * BMI T3-T0 0.00 0.00 0.89 − 0.01–0.01
ALND * nodal stage * axillary radiation − 298.79 187.54 0.11 − 668.96–71.37
ALND * nodal stage * BMI T3-T0 − 0.80 1.87 0.69 − 6.04–4.45
ALND * axillary radiation * BMI T3-T0 310.77 189.37 0.10 − 62.99–684.54
Nodal stage * axillary radiation * BMI
T3-T0
− 0.00 0.48 1.00 − 0.954–0.95
ALND axillary lymph node dissection, BMI body mass index
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